Mastitis is the second most common type of cancer in women, states WHO, and is one of the paramount global concerns. Global around 200,000 new cases are being registered every year and the digits are continuously increasing. Statics show that the Mastitis is prevailing in developed countries like UK, US & Australia & their women are more prone to the Breast Cancer.
This doesn’t mean that women from developing countries like India & China are out of the Breast Cancer’s radar. On the contrary they are more vulnerable than women from the developing countries. Unavailability of proper treatment due to the lack of funds and unawareness towards the government’s programmes is killing them more than the disease is.
The biggest hue is that India is the country filled with largest number of expert doctors & techies. Despite of several adversities they are discovering more & more treatment techniques. Besides, India has Ayurveda & yoga but again politics & unawareness together is dominantly restricting people to reach to these novel treatments.
Definitely, technological advancement in medical science & biotechnology has improved improves the outlook for many women diagnosed; but again the recovery is still challenging as survivors adjust to the scars that remain mentally and physically.
Surprisingly, the Mastitis market is still accruing vastly & the changing lifestyle is to be blamed. Improving economy is proving to be a blessing in disguise that is increasing the affordability of people increasing access to the modern life and growing alcoholism in women is again a dominant risk factor developing breast cancer.
Acknowledging the kind of traction the market is garnering globally owing to the technological advancements that are sufficiently controlling the spread of the disease; Market Research Future has recently published a study report giving out the complete market prognosis and innovations driving the market growth. In its analysis, MRFR foretells that the global Mastitis market is of projected to register a staggering CAGR of 9.2% accruing pervasively during 2017 – 2023.
In addition to the adoption of unhealthy lifestyle other factors driving the market growth include, increasing female geriatric population, exposure to harmful radiation, heredity reasons and genetic mutations (abnormal changes) coupled with the increasing governmental initiatives. Unavailability of absolute treatment presages the large scope for the market to evolve further and prompting to pharmaceutical companies to invest increasingly in R&D to discover novel more effective medicines.
Conversely, high costs pertaining to the treatments, long approval time for the drugs along with the adverse effects associated with therapies are restricting the market growth. Nevertheless, advent Mastitis treatments brought forward during the past few years and the approval of medication called CDK45 Inhibitors, has impacted the market in a big way. CDK45 Inhibitors when used in combination with endocrine therapy for positive Mastitis hormone-receptor, patients have shown improvements in survival – up to 10 months. Additionally factors such as innovations, e.g. 3-D digital tomosynthesis imaging, Mammography allowing a more clear view through dense breast tissue and changes such as signed bill into law that allows commercial insurance providers to cover breast screening, including 3-D mammography are expected to provide impetus to the market growth.
Global Mastitis Market – Segments
For the convenience of the report and enhanced understanding; Market is segmented in to 4 key dynamics;
By Types : Comprises Invasive Lobular Carcinoma, Invasive Ductal Carcinoma, and other.
By Treatment : Chemotherapy (Antimetabolites, Anthracyclines, Taxanes & Alkylating Agents), Surgery & Radiation Therapy, Targeted Therapy (Tyrosine Kinase Inhibitors &Monoclonal Antibodies), Biologic Therapy, Hormone Therapy (selective estrogen-receptor modulators (SERMs), aromatase inhibitors) etc.
By End Users : Private Pharmacies and Hospital Pharmacies, etc.
By Regions : APAC, North America, Europe, and Rest of the World.
Segment Chemotherapy holds the largest share as in 45% of the market.
Global Mastitis Market – Geographical Analysis
North America dominates the Mastitis market globally; the growth is largely supported by the US. Market is driven by the increasing prevalence of the disease fuelled by the consequences of the wrong lifestyle. Factors such as technological advances coupled with the increasing healthcare expenditure support the market growth. Europe region is the second largest market for the Mastitis market. Asia Pacific is emerging as the fastest growing market owing to the rising medical tourism market in the region.
Global Mastitis Market – Competitive Landscape
Mastitis Market Key players Bayer AG (Germany), Oncothyreon Inc (US), OncoGenex (US), Apthera Inc. (UK), Zoetis Inc. (US), Boehringer Ingelheim GmbH (Germany), Merck Co. & Inc. (US), Astellas Pharma Inc. (Japan), Pfizer Inc. (US), Novartis AG (Switzerland), Sanofi SA (France), Hoffmann-La Roche AG (Switzerland)
Related Report:
General Hospital Supplies Devices Market
English
Arabic
Français
Español
Português
Türkçe
Dutch
Italiano
Russian
Romaian